Related Experiment Video

Updated: Jun 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Atrial-selective drugs for treatment of atrial fibrillation

U Ravens1, T Christ

  • 1Department of Pharmacology and Toxicology, Dresden University of Technology, Fetscherstr. 74, 01307, Dresden, Deutschland. Ravens@rcs.urz.tu-dresden.de

Herzschrittmachertherapie & Elektrophysiologie
|November 18, 2010
PubMed

Insights

New atrial fibrillation drugs aim for high atrial selectivity, targeting specific ion channels to minimize side effects. This approach seeks safer, effective antiarrhythmic treatments for persistent arrhythmias.

Area of Science:

  • Cardiology
  • Pharmacology
  • Electrophysiology

Background:

  • Atrial fibrillation (AF) poses a high risk of thromboembolic events, necessitating anticoagulation.
  • Catheter ablation is effective but costly and time-consuming for widespread AF treatment.
  • Conventional antiarrhythmic drugs have moderate efficacy and significant side effects.

Purpose of the Study:

  • To explore the development of new antifibrillatory drugs with high atrial selectivity.
  • To achieve antiarrhythmic actions specifically in the atria, avoiding ventricular proarrhythmia.
  • To identify novel drug targets for AF treatment.

Main Methods:

  • Investigating multichannel blockers with atrial-selective properties.
  • Targeting ion channels predominantly expressed in the atria, such as Kv1.5 (I(Kur)) and Kir 3.1/3.4 (I(K,ACh)).
  • Exploring rapid Na(+) channel blockers and disease-specific targets for atrial selectivity.

Main Results:

  • Atrial selectivity is achievable by targeting specific atrial ion channels.
  • Differences in atrial and ventricular action potentials can be exploited for selective drug action.
  • Disease-specific processes offer avenues for developing targeted antiarrhythmic therapies.

Conclusions:

  • Atrial-selective drug development offers a promising strategy for safer and more effective AF treatment.
  • Targeting specific ion channels like Kv1.5 and Kir3.x is key to achieving atrial selectivity.
  • Future research should focus on developing drugs with enhanced atrial selectivity to improve patient outcomes in AF.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Robotic Ablation of Atrial Fibrillation11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...